Don’t expect vaccine makers’ shares to jump despite ongoing demand for boosters, treatments

When global vaccination rates against COVID-19 were on the rise a year ago, investors wondered what the coming months would hold for vaccine makers. Would demand ease or would new variants mean an ever-increasing demand for boosters?

The answer began to emerge in March when the Delta variant arrived, followed in late fall by Omicron. Managing the pandemic would be ongoing, with steady demand for treatments and tests. That realization made it a good year for vaccine makers.

Read more here.